GCTK News

Lkahi Therapeutics, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced Qare, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. Introduced on National GLP-1 Day...

Lkahi Therapeutics, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that it will partner with Pepperdine E2B (Education to Business) to engage students in its ai2 Pipeline initiative during the upcoming academic year. The collaboration is intended to provide students with hands-on...

The market is watching a diverse group of companies as catalysts converge. NeOnc Technologies Holdings (NASDAQ:NTHI) attracted fresh Wall Street coverage around its brain-cancer pipeline; Profusa (NASDAQ:PFSA) is moving closer to a potential European regulatory milestone; Sky Quarry (NASDAQ:SKYQ) restarted Nevada's Eagle Springs Refinery; Glucotrack (NASDAQ:GCTK) is turning its Lōkahi asset-discovery platform toward external revenue; while Greenland Mines Ltd. (NASDAQ:GRML) and Greenland Energy Company (NASDAQ:GLND) are advancing separate projects in Greenland.

GlucoTrack subsidiary Lokahi Therapeutics secured its first external fee-for-service partnership with nonprofit Innovate GBM for glioblastoma research.read more...

The markets are producing a striking mix of catalysts, with NeOnc (NASDAQ:NTHI), Kraig Biocraft Laboratories (OTCQB:KBLB), Profusa (NASDAQ:PFSA), Sky Quarry (NASDAQ: SKYQ), Glucotrack (NASDAQ:GCTK) and Greenland Mines (NASDAQ:GRML) all generating fresh developments.

Glucotrack, Inc. (NASDAQ: GCTK) (Glucotrack or the Company) today announced the pricing of a best efforts public offering of 169,388 shares of common stock at a price of $2.04 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 1,350,220...

Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to $3.99. Theread more...

GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.read more...

GlucoTrack shares soar 80% after-hours as Lokahi Therapeutics signs first external glioblastoma licensing partnership with Innovate GBM.read more...